Journal — News
Regulatory motion, FDA updates, and editorial briefs.
Jul 14, 2026 · 4 min
A Nature analysis suggests cardioprotective effects track the dose patients actually sustain rather than the pounds they drop, with implications for GLP-1 dosing strategies.
@peptidedesk
Jul 14, 2026 · 4 min
Sandoz's accepted FDA applications for generic tirzepatide signal potential competition in the GLP-1 market, though a broader biosimilar development gap persists.
@peptidedesk
Jul 14, 2026 · 4 min
Cleveland Clinic publishes an educational overview comparing the two dominant GLP-1 receptor agonists, breaking down differences in mechanism, efficacy, and clinical context for patients and researchers tracking metabolic peptide developments.
@peptidedesk
Jul 14, 2026 · 4 min
A retrospective Cureus study adds real-world data on pairing a GLP-1 receptor agonist with an SGLT2 inhibitor for type 2 diabetes.
@peptidedesk
Jul 14, 2026 · 4 min
A reported Phase 3 readout for a GLP-3 receptor agonist hints at a next-generation metabolic peptide class. The data is preliminary and sourced through a single news aggregator—here is what is actually known.
@peptidedesk
Jul 14, 2026 · 4 min
A Discover Magazine report ties a spike in poison control calls to two avoidable semaglutide measurement mistakes, underscoring safety risks as compounded and research-grade GLP-1 products circulate widely.
@peptidedesk
Jul 14, 2026 · 4 min
The UK's General Pharmaceutical Council warns consumers about counterfeit online pharmacies as demand for GLP-1 weight-loss treatments surges following the introduction of oral semaglutide.
@peptidedesk
Jul 13, 2026 · 4 min
New research hints that tirzepatide's weight-loss effects may extend beyond appetite suppression, potentially altering how the body expends energy.
@peptidedesk
Jul 13, 2026 · 4 min
Singapore's health authority has updated the Wegovy label to include a higher dose of semaglutide, citing STEP UP trial evidence. Here's what the regulatory move signals for GLP-1 peptide access.
@peptidedesk
Jul 13, 2026 · 4 min
A preview of anticipated obesity drug data at ADA 2026, covering next-generation peptide therapeutics retatrutide, CagriSema, and oral GLP-1 candidates expected to shape the competitive GLP-1 landscape.
@peptidedesk
Jul 10, 2026 · 4 min
A quality setback at Dr. Reddy's Laboratories pushes back the company's semaglutide supply timeline and rattles investors, with potential implications for the generic GLP-1 competitive landscape.
@peptidedesk
Jul 9, 2026 · 4 min
A Washington Post report spotlights the surging underground interest in retatrutide, an experimental triple-agonist peptide being used off-label for weight loss before it clears regulatory hurdles.
@peptidedesk
Jul 9, 2026 · 4 min
Novo Nordisk is backing Vivani Medical to develop a sustained-release semaglutide implant, signaling fresh industry appetite for depot delivery of GLP-1 therapeutics beyond weekly injections.
@peptidedesk
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.